drugset / Trial / NCT03791060
Secukinumab for NLD (Cosentyx) in Patients With Necrobiosis Lipoidica Diabeticorum (NLD)
Phase 2
Terminated
4 enrolled
Beth Israel Deaconess Medical Center
Novartis Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
This study investigates the efficacy of secukinumab in necrobiosis lipoidica diabeticorum (NLD).
Timeline
- Start
- 2019-04-03
- Primary completion
- 2021-01-17
- Completion
- 2021-04-10
Outcome
Outcome not reported
Stopped: “Study halted prematurely due COVID-19 pandemic and did not resume; participants are no longer being examined or receiving intervention.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Secukinumab | Monoclonal antibody | 300 mg | Subcutaneous |